Circulating IGF system and treatment outcome in epithelial ovarian cancer

Endocrine-Related Cancer

Volumn 21, Issue 2, 2014, Pages 217-229

  Huang, Yu Fang ^a   Cheng, Wen Fang ^b   Wu, Yu Peng ^a   Cheng, Ya Min ^a   Hsu, Keng Fu ^a   Chou, Cheng Yang ^a,c  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Epithelial ovarian cancer; Insulin like growth factor; Insulin like growth factor binding protein; Prognosis; Response to chemotherapy

Indexed keywords

SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; EARLY CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; TREATMENT DURATION; TREATMENT OUTCOME;

EPITHELIAL OVARIAN CANCER; INSULIN-LIKE GROWTH FACTOR; INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN; PROGNOSIS; RESPONSE TO CHEMOTHERAPY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PREOPERATIVE PERIOD; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84899861747     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-13-0274     Document Type: Article

References (54)

1. Allen NE, Key TJ, Appleby PN, Travis RC, Roddam AW, Rinaldi S, Egevad L, Rohrmann S, Linseisen J, Pischon T et al. 2007 Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiology, Biomarkers & Prevention 16 1121-1127. (doi:10.1158/1055-9965.EPI-06-1062)
2. Baron-Hay S, Boyle F, Ferrier A & Scott C 2004 Elevated serum insulin-like growth factor binding protein-2 as a prognostic marker in patients with ovarian cancer. Clinical Cancer Research 10 1796-1806. (doi:10.1158/1078- 0432.CCR-0672-2)
3. Beauchamp MC, Yasmeen A, Knafo A & Gotlieb WH 2010 Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancer. Journal of Oncology 2010 257058. (doi:10.1155/2010/257058)
4. Brokaw J, Katsaros D, Wiley A, Lu L, Su D, Sochirca O, de la Longrais IA, Mayne S, Risch H & Yu H 2007 IGF-I in epithelial ovarian cancer and its role in disease progression. Growth Factors 25 346-354. (doi:10.1080/ 08977190701838402)
5. Cao Z, Liu LZ, Dixon DA, Zheng JZ, Chandran B & Jiang BH 2007 Insulinlike growth factor-I induces cyclooxygenase-2 expression via PI3K, MAPK and PKC signaling pathways in human ovarian cancer cells. Cellular Signalling 19 1542-1553. (doi:10.1016/j.cellsig.2007.01.028)
6. Chang JT, Gatza ML, Lucas JE, Barry WT, Vaughn P & Nevins JR 2011 SIGNATURE: a workbench for gene expression signature analysis. BMC Bioinformatics 12 443. (doi:10.1186/1471-2105-12-443)
7. Chi F, Wu R, Zeng YC, Xing R & Liu Y 2013 Circulation insulin-like growth factor peptides and colorectal cancer risk: an updated systematic review and meta-analysis. Molecular Biology Reports 40 3583-3590. (doi:10.1007/s11033- 012-2432-z)
8. Cho KR & Shih IeM 2009 Ovarian cancer. Annual Review of Pathology 4 287-313. (doi:10.1146/annurev.pathol.4.110807.092246)
9. Duggan C, Wang CY, Neuhouser ML, Xiao L, Smith AW, Reding KW, Baumgartner RN, Baumgartner KB, Bernstein L, Ballard-Barbash R et al. 2013 Associations of insulin-like growth factor and insulin-like growth factor binding protein-3 with mortality in women with breast cancer. International Journal of Cancer 132 1191-1200. (doi:10.1002/ijc.27753)
10. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M et al. 2009 New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer 45 228-247. (doi:10.1016/j.ejca.2008.10.026)
11. Flyvbjerg A, Mogensen O, Mogensen B & Nielsen OS 1997 Elevated serum insulin-like growth factor-binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: correlation with cancer antigen 125 and tumor-associated trypsin inhibitor. Journal of Clinical Endocrinology and Metabolism 82 2308-2313. (doi:10.1210/jc.82.7.2308)
12. Fuchs CS, Goldberg RM, Sargent DJ, Meyerhardt JA, Wolpin BM, Green EM, Pitot HC & Pollak M 2008 Plasma insulin-like growth factors, insulinlike binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741. Clinical Cancer Research 14 8263-8269. (doi:10.1158/1078-0432.CCR-08-0480)
13. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, Li J, Ho GY, Xue X, Anderson GL et al. 2009 Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. Journal of the National Cancer Institute 101 48-60. (doi:10.1093/jnci/djn415)
14. Hartmann LC, Lu KH, Linette GP, Cliby WA, Kalli KR, Gershenson D, Bast RC, Stec J, Iartchouk N, Smith DI et al. 2005 Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clinical Cancer Research 11 2149-2155. (doi:10.1158/1078-0432.CCR-04-1673)
15. Heitz F, Harter P, Barinoff J, Beutel B, Kannisto P, Grabowski JP, Heitz J, Kurzeder C & du Bois A 2012 Bevacizumab in the treatment of ovarian cancer. Advances in Therapy 29 723-735. (doi:10.1007/s12325-012-0041-9)
16. Huang YF, Shen MR, Hsu KF, Cheng YM & Chou CY 2008 Clinical implications of insulin-like growth factor 1 system in early-stage cervical cancer. British Journal of Cancer 99 1096-1102. (doi:10.1038/sj.bjc.6604661)
17. Huang GS, Brouwer-Visser J, Ramirez MJ, Kim CH, Hebert TM, Lin J, Arias-Pulido H, Qualls CR, Prossnitz ER, Goldberg GL et al. 2010 Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer. Clinical Cancer Research 16 2999-3010. (doi:10.1158/1078-0432.CCR-09-3233)
18. Jazaeri AA, Awtrey CS, Chandramouli GV, Chuang YE, Khan J, Sotiriou C, Aprelikova O, Yee CJ, Zorn KK, Birrer MJ et al. 2005 Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clinical Cancer Research 11 6300-6310. (doi:10.1158/1078-0432.CCR-04-2682)
19. Jhamb N & Lambrou NC 2010 Epidemiology and clinical presentation of ovarian cancer. In Early Diagnosis and Treatment of Cancer: Ovarian Cancer, pp 17-32. Eds RE Bristow & DK Armstrong. Philadelphia, PA: Sauders Elsevier.
20. Kanety H, Kattan M, Goldberg I, Kopolovic J, Ravia J, Menczer J & Karasik A 1996 Increased insulin-like growth factor binding protein-2 (IGFBP-2) gene expression and protein production lead to high IGFBP-2 content in malignant ovarian cyst fluid. British Journal of Cancer 73 1069-1073. (doi:10.1038/bjc.1996.206)
21. Karasik A, Menczer J, Pariente C & Kanety H 1994 Insulin-like growth factor-I (IGF-I) and IGF-binding protein-2 are increased in cyst fluids of epithelial ovarian cancer. Journal of Clinical Endocrinology and Metabolism 78 271-276. (doi:10.1210/jc.78.2.271)
22. Katsaros D, Yu H, Levesque MA, Danese S, Genta F, Richiardi G, Fracchioli S, Khosravi MJ, Diamandi A, Gordini G et al. 2001 IGFBP-3 in epithelial ovarian carcinoma and its association with clinico-pathological features and patient survival. European Journal of Cancer 37 478-485. (doi:10.1016/S0959-8049(00) 00423-8)
23. Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura E et al. 2009 Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 374 1331-1338. (doi:10.1016/S0140-6736(09)61157-0)
24. Lancaster JM, Sayer RA, Blanchette C, Calingaert B, Konidari I, Gray J, Schildkraut J, Schomberg DW, Marks JR & Berchuck A 2006 High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels. International Journal of Gynecological Cancer 16 1529-1535. (doi:10.1111/j.1525-1438.2006.00623.x)
25. Lau MT & Leung PC 2012 The PI3K/Akt/mTOR signaling pathway mediates insulin-like growth factor 1-induced E-cadherin down-regulation and cell proliferation in ovarian cancer cells. Cancer Letters 326 191-198. (doi:10.1016/j.canlet.2012.08.016)
26. Lee KR, Russell P, Tavassoli FA, Buckley CH, Prat J, Pisani P, Dietel M, Schwartz P, Gersell DJ, Goldgar DE et al. 2003 Tumours of the ovary and peritoneum. In Pathology and Genetics of Tumor of the Breast and Female Genital Organs, pp 114-202. Eds FA Tavassoli & P Devilee. Lyon: IARC Press.
27. Lee EJ, Mircean C, Shmulevich I, Wang H, Liu J, Niemistö A, Kavanagh JJ, Lee JH & Zhang W 2005 Insulin-like growth factor binding protein 2 promotes ovarian cancer cell invasion. Molecular Cancer 4 7. (doi:10.1186/1476-4598-4-7)
28. Lu L, Katsaros D, Wiley A, Rigault de la Longrais IA, Risch HA, Puopolo M & Yu H 2006 The relationship of insulin-like growth factor-II, insulin-like growth factor binding protein-3, and estrogen receptor-A expression to disease progression in epithelial ovarian cancer. Clinical Cancer Research 12 1208-1214. (doi:10.1158/1078-0432.CCR-05-1801)
29. Penson RT, Dizon DS, Cannistra SA, Roche MR, Krasner CN, Berlin ST, Horowitz NS, Disilvestro PA, Matulonis UA, Lee H et al. 2010 Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced Müllerian tumors. Journal of Clinical Oncology 28 154-159. (doi:10.1200/JCO.2009.22.7900)
30. Pham TM, Fujino Y, Kikuchi S, Tamakoshi A, Yatsuya H, Matsuda S, Yoshimura T & JACC Study Group 2007 A nested case-control study of stomach cancer and serum insulin-like growth factor (IGF)-1, IGF-2 and IGF-binding protein (IGFBP)-3. European Journal of Cancer 43 1611-1616. (doi:10.1016/j.ejca. 2007.04.014)
31. Pollak M 2008a Targeting insulin and insulin-like growth factor signalling in oncology. Current Opinion in Pharmacology 8 384-392. (doi:10.1016/j.coph.2008.07.004)
32. Pollak M 2008b Insulin and insulin-like growth factor signalling in neoplasia. Nature Reviews. Cancer 8 915-928. (doi:10.1038/nrc2536)
33. Pollak M 2012 The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology. Clinical Cancer Research 18 40-50. (doi:10.1158/1078-0432.CCR-11-0998)
34. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM & Egger M 2004 Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363 1346-1353. (doi:10.1016/S0140-6736(04)16044-3)
35. Rinaldi S, Cleveland R, Norat T, Biessy C, Rohrmann S, Linseisen J, Boeing H, Pischon T, Panico S, Agnoli C et al. 2010 Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies. International Journal of Cancer 126 1702-1715. (doi:10.1002/ijc.24927)
36. Rohrmann S, Grote VA, Becker S, Rinaldi S, Tjønneland A, Roswall N, Grønbæk H, Overvad K, Boutron-Ruault MC, Clavel-Chapelon F et al. 2012 Concentrations of IGF-I and IGFBP-3 and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition. British Journal of Cancer 106 1004-1010. (doi:10.1038/bjc.2012.19)
37. Rowlands MA, Holly J, Hamdy F, Phillips J, Goodwin L, Marsden G, Gunnell D, Donovan J, Neal D & Martin R 2012 Serum insulin-like growth factors and mortality in localised and advanced clinically detected prostate cancer. Cancer Causes & Control 23 347-354. (doi:10.1007/s10552-011-9883-8)
38. Rustin GJ, Quinn M, Thigpen T, Du Bois A, Pujade-Lauraine E, Jakobsen A, Eisenhauer E, Sagae S, Greven K, Vergote I et al. 2004 Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). Journal of the National Cancer Institute 96 487-488. (doi:10.1093/jnci/djh081)
39. Sayer RA, Lancaster JM, Pittman J, Gray J, Whitaker R, Marks JR & Berchuck A 2005 High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer. Gynecologic Oncology 96 355-361. (doi:10.1016/j. ygyno.2004.10.012)
40. Scagliotti GV & Novello S 2012 The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors. Cancer Treatment Reviews 38 292-302. (doi:10.1016/j.ctrv. 2011.07.008)
41. Schaffer A, Koushik A, Trottier H, Duarte-Franco E, Mansour N, Arseneau J, Provencher D, Gilbert L, Gotlieb W, Ferenczy A et al. 2007 Insulin-like growth factor-I and risk of high-grade cervical intraepithelial neoplasia. Cancer Epidemiology, Biomarkers & Prevention 16 716-722. (doi:10.1158/1055-9965.EPI-06-0924)
42. Schillaci R, Galeano A, Becu-Villalobos D, Spinelli O, Sapia S & Bezares RF 2005 Autocrine/paracrine involvement of insulin-like growth factor-I and its receptor in chronic lymphocytic leukaemia. British Journal of Haematology 130 58-66. (doi:10.1111/j.1365-2141.2005.05579.x)
43. Schips L, Zigeuner R, Ratschek M, Rehak P, Rüschoff J & Langner C 2004 Analysis of insulin-like growth factors and insulin-like growth factor I receptor expression in renal cell carcinoma. American Journal of Clinical Pathology 122 931-937. (doi:10.1309/G7PY0RE7T86HHQYV)
44. Serin IS, Tanriverdi F, Yilmaz MO, Ozcelik B & Unluhizarci K 2008 Serum insulin-like growth factor (IGF)-I, IGF binding protein (IGFBP)-3, leptin concentrations and insulin resistance in benign and malignant epithelial ovarian tumors in postmenopausal women. Gynecological Endocrinology 24 117-121. (doi:10.1080/09513590801895559)
45. Siegel R, Naishadham D & Jemal A 2012 Cancer statistics, 2012. CA: A Cancer Journal for Clinicians 62 10-29. (doi:10.3322/caac.20138)
46. Spentzos D, Cannistra SA, Grall F, Levine DA, Pillay K, Libermann TA & Mantzoros CS 2007 IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer. Endocrine-Related Cancer 14 781-790. (doi:10.1677/ERC-06-0073)
47. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brünner N, Chan DW, Babaian R, Bast RC Jr, Dowell B, Esteva FJ et al. 2008 National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clinical Chemistry 54 e11-e79. (doi:10.1373/clinchem.2008.105601)
48. Suzuki S, Kojima M, Tokudome S, Suzuki K, Ozasa K, Ito Y, Inaba Y, Tajima K, Nakachi K, Watanabe Y et al. 2009 Insulin-like growth factor (IGF)-I, IGF-II, IGF binding protein-3, and risk of colorectal cancer: a nested case-control studyinthe Japan Collaborative Cohort Study. Asian Pacific Journal of Cancer Prevention 10 (Suppl) 45-49.
49. Torng PL, Lee YC, Huang CY, Ye JH, Lin YS, Chu YW, Huang SC, Cohen P, Wu CW & Lin CT 2008 Insulin-like growth factor binding protein-3 (IGFBP-3) acts as an invasion-metastasis suppressor in ovarian endometrioid carcinoma. Oncogene 27 2137-2147. (doi:10.1038/sj.onc.1210864)
50. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B et al. 2008 Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clinical Cancer Research 14 5198-5208. (doi:10.1158/1078-0432.CCR-08-0196)
51. Vergote I, Rustin GJ, Eisenhauer EA, Kristensen GB, Pujade-Lauraine E, Parmar MK, Friedlander M, Jakobsen A & Vermorken JB 2000 Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. Journal of the National Cancer Institute 92 1534-1535. (doi:10.1093/jnci/92.18.1534)
52. Waksmański B, Dudkiewicz J & Kowalski T 2001 Changes in insulin-like growth factor I, 17-b-estradiol, and progesterone in postmenopausal women with benign and malignant ovarian tumours. Medical Science Monitor 7 919-923.
53. Walker G, MacLeod K, Williams AR, Cameron DA, Smyth JF & Langdon SP 2007 Insulin-like growth factor binding proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine responsiveness in patients with ovarian cancer. Clinical Cancer Research 13 1438-1444. (doi:10.1158/1078-0432.CCR-06-2245)
54. Weroha SJ & Haluska P 2012 The insulin-like growth factor system in cancer. Endocrinology and Metabolism Clinics of North America 41 335-350. (doi:10.1016/j.ecl.2012.04.014)